The FDA grants Fast Track designation to BNT113 for treating HPV16+ head and neck squamous cell carcinoma expressing PD-L1 in the first-line setting.
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results